252 related articles for article (PubMed ID: 30504298)
1. Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.
Giralt S; Seifter E
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):103-109. PubMed ID: 30504298
[TBL] [Abstract][Full Text] [Related]
2. Treatment approach for young, fit, newly diagnosed multiple myeloma patients.
Usmani SZ; Seifter E
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):97-102. PubMed ID: 30504297
[No Abstract] [Full Text] [Related]
3. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies in monoclonal gammopathies.
Niesvizky R
Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
[TBL] [Abstract][Full Text] [Related]
6. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Baertsch MA; Hundemer M; Hillengass J; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):258-261. PubMed ID: 28840598
[TBL] [Abstract][Full Text] [Related]
8. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma: new uses for available agents, excitement for the future.
Anderson KC
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide (Pomalyst) for multiple myeloma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
[No Abstract] [Full Text] [Related]
11. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Hussain MJ; Robinson MM; Hamadeh I; Arnall J; Bhutani M; Atrash S; Friend R; Pineda-Roman M; Symanowski JT; Usmani SZ; Voorhees PM
Br J Haematol; 2019 Jul; 186(1):140-144. PubMed ID: 30536372
[No Abstract] [Full Text] [Related]
12. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
14. Management of multiple myeloma in the relapsed/refractory patient.
Sonneveld P
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):508-517. PubMed ID: 29222299
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
16. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
17. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
